FRM
CGON icon

Fox Run Management’s CG Oncology CGON Stock Holding History

Fox Run Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$211K Buy
+3,296
New +$187K 0.04% 751
2025
Q2 		– Sell
-16,676
Closed -$408K – 907
2025
Q1 		$408K Buy
+16,676
New +$469K 0.06% 570

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fox Run Management's CGON Position: Q1 2026 in Review

Fox Run Management opened a new position in CG Oncology (CGON) in Q1 2026: 3,296 shares worth $211K. The stake represents 0.04% of the portfolio and ranks #751 among its holdings. This is a return to the name: Fox Run Management previously reported a position in CGON as recently as Q1 2025.

Fox Run Management first reported a position in CGON in Q1 2025 and has held it in 2 quarters since. The position peaked at $408K in Q1 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Fox Run Management held 3,296 shares of CG Oncology worth $211K as of Q1 2026.
  • CG Oncology was a new Fox Run Management position in Q1 2026.
  • CG Oncology made up 0.04% of Fox Run Management's portfolio in Q1 2026, its #751 holding.
  • Fox Run Management first reported a position in CG Oncology in Q1 2025 and has held it in 2 quarters since.
  • Fox Run Management's CG Oncology position peaked at $408K in Q1 2025.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.